A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals
Latest Information Update: 08 Mar 2024
At a glance
- Drugs VGX 3100 (Primary)
- Indications Anal intraepithelial neoplasia; Human papillomavirus infections; Squamous cell cancer
- Focus Therapeutic Use
- 30 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2023 Planned End Date changed from 15 May 2024 to 20 Sep 2029.
- 05 Jun 2023 Planned primary completion date changed from 15 May 2024 to 20 Sep 2029.